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DKK3 CAN PREVENT CARTILAGE DEGRADATION AND MODULATE
TGFBETA AND WNT SIGNALLING
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East Anglia, Norwich, United Kingdom; 2Univ. of Oxford, Oxford, United
Kingdom
Purpose:We have previously shown that Dkk3 expression is increased
in OA cartilage and synovium. Levels of Dkk3 in synovial ﬂuid are also
increased in individuals with tricompartmental OA and after arthros-
copy. The factors regulating Dkk3 expression in cartilage and the effect
of Dkk3 on chondrocyte function are poorly ascribed.
Correct regulation of cell signalling pathways is integral to cartilage
homeostasis and thus the prevention of OA pathogenesis. Dkk3 is
a member of the Dkk family of Wnt antagonists and therefore may
impact on chondrocyte biology through interaction with the Wnt
pathway. Dkk3 has also been found to inﬂuence TGFb signalling in other
cell systems.
Methods: Expression of Dkk3 was assessed in primary human articular
chondrocytes (HAC) following treatment with interleukin-1 (IL1) and
oncostatin-M (OSM). The effect of Dkk3 on IL1/OSM-induced proteo-
glycan and collagen release from explants of bovine nasal (BNC)- and
primary human-cartilage was assessed. SW1353 chondrosarcoma cells
were treated with Dkk3+/-Wnt3a, TGFb and Activin and TOPFlash and
CAGA luciferase reporters used to measure Wnt and Smad signalling.
RNA was extracted from primary HAC treated with Dkk3+/-TGFb or
Wnt3a. ADAM12 and TIMP3 expression were measured to assess TGFb
signalling and AXIN2 to assess Wnt signalling. Micromass HAC were
treated with Wnt3a +/- Dkk3 and proteoglycan output assessed using
alcian blue staining. b-catenin was silenced in primary HAC prior to
TGFb and Activin treatment. Dkk3 was silenced in primary HAC for
microarray analysis.
Results: Dkk3 expression was decreased in primary HAC following IL1/
OSM treatment. In BNC explants, IL1/OSM-induced proteoglycan
release was inhibited by Dkk3. Dkk3 antagonized Wnt signalling,
decreasing Wnt3a-induced AXIN2 expression and luciferase expression
from the TOPFlash reporter. Dkk3 also antagonized Wnt3a-induced
reductions in proteoglycan production in micromass cultures. Inter-
estingly, Dkk3 enhanced TGFb signalling, increasing TGFb-induced
TIMP3 and ADAM12 expression and TGFb-induced luciferase from the
CAGA-luc reporter. In contrast Dkk3 antagonized Activin-induced
CAGA-luc activity, TIMP3 and ADAM12 expression. b-catenin knock-
down did not signiﬁcantly alter TGFb- or Activin-induced expression of
TIMP3 or ADAM12, suggesting that Dkk3-effects on these pathways is
not mediated solely by inhibition of Wnt signalling. Knockdown of
Dkk3 in primary HAC resulted in altered expression of a number of
genes, with decreases in DICER and BMPR2, and increases in CTGF
detected.
Conclusions: OA pathogenesis is likely regulated by a multitude of
factors relating to cell signalling including the balance of cytokines in
the articular joint. Dkk3 expression is increased in OA but can be
regulated IL1 and OSM. This suggests a balance of Dkk3 effects
depending upon the biological stimuli within the cartilage. Dkk3 may
act in a protective role in the presence of inﬂammatory cytokines as
exempliﬁed by its ability to inhibit matrix loss. Dkk3 knockdown
decreases DICER expression and thus changes in Dkk3 expression in OA1063-4584/$ – see front matter  2012 Published by Elsevier Ltd on behalf of Osteoartmay alter chondrocyte phenotype through alterations in miRNA
activity. The ability of Dkk3 to antagonize Wnt, enhance TGFb and
antagonize Activin signalling would have multiple effects on chon-
drocyte activity. These results imply that Dkk3 could inﬂuence multiple
OA-relevant processes, protect cartilage from degradation and be
important in cartilage development and homeostasis.
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Purpose: Osteoarthritic (OA) chondrocyte are characterized by alto-
gether DNA damage accumulation, eroded telomeres, expression of
senescence marker such as p16Ink4a and establishment of one speciﬁc
secretome including IL-1b, IL-8 and MMP-1/-3/-13. Recent data have
proposed that tissue speciﬁc accumulation of p16Ink4a-positive cells
would be deleterious for the tissue function and could be the conse-
quence of the inherent age-associated disorders. Here we evaluate the
role of p16Ink4a-dependent pathway and its epigenetic regulation by
microRNAs in osteoarthritis-associated phenotypes.
Methods:We performed a genome wide miRNA-array analysis in order
to identify microRNAs regulating senescence-associated phenotypes
found in OA. We used primary OA chondrocytes in 3D culture, IL-1b
treatment and gain or loss of function experiments to validate their
regulatory effects on senescence-associated targets. chondrogenic
differentiation was induced by culture of Mesenchymal Stromal Cells in
micropellets in inductive medium for 21 days. Expression of chon-
drocyte markers was performed by RT-qPCR.
Results: By miR-array analysis, we identiﬁed the down-regulation
of miR-24, one previously described epigenetic regulator of
p16Ink4a. Accordingly, miR-24 expression in chondrocytes is
repressed upon IL-1 b treatment while p16Ink4a protein accumu-
lates. Based on gain or loss of functions approaches, our results
suggest that miR-24 down regulation or p16Ink4A overexpression,
are sufﬁcient to trigger chondrocyte premature aging characterized
by activation of p16Ink4a-MMP-1 axis as shown by RT-qPCR and
elisa. This reverse correlation is also observed during hypertrophic
stage induced by an in vitro chondrogenic differentiation of
mesenchymal stromal cells.
Conclusions: Altogether, our data show that, in Il-1b -treated chon-
drocytes, miR-24 expression is down-regulated leading to p16ink4A
accumulation. In turn, p16Ink4a controls the expression of one osteo-
arthritis-inducing enzyme, MMP-1 this probably via the transcriptional
induction of the transcription factor, ZNF-410. Future experiments are
required to validate this last hypothesis and would open new
perspectives for putative pharmacological targets to delay cartilage
premature aging or other p16ink4a-dependent diseases.hritis Research Society International.
